

PRESS RELEASE

Lund, SWEDEN – May 23, 2011



HANSA MEDICAL PUBLISHES FINANCIAL INFORMATION FROM ITS PROSPECTUS REGARDING THE NEW SHARE ISSUE

On 12 May 2011, Hansa Medical's annual meeting of shareholders resolved to execute a new share issue of SEK 29 million, with preferential rights to Hansa Medical's shareholders. Hansa Medical, today, makes official those details which have not been previously published, but which are now available in the new share issue prospectus.

Financial position as at 31 March 2011

The Group's cash and bank balances amounted at 31 March to just under MSEK 0.1 and equity amounted to MSEK 27.2. Net liabilities amounted to MSEK 9.4, of which MSEK 7.8 was comprised of bridge financing in the form of loans. Short-term liabilities amounted to MSEK 2.3 and were comprised primarily of accounts payable. The following tables show the Group's net liabilities as at 31 March 2011.

NET LIABILITIES, CURRENT AND LONG-TERM, KSEK	Group 31 MARCH 2011	EQUITY AND LIABILITIES, KSEK	Group 31 MARCH 2011
Cash and bank	82	<i>Current liabilities</i>	
Liquid funds	-	With guarantees	-
Easily realised securities	-	With collateral	-
Total liquidity	82	Unsecured credits	2 289
Short-term receivables	609	Total current liabilities	2 289
Short-term bank liabilities	-	<i>Long-term liabilities</i>	
Current portion of long-term liabilities	-	With guarantees	-
Other current liabilities	2 289	With collateral	-
Current liabilities	2 289	Unsecured credits	7 800
Net current liabilities	1 598	Total long-term liabilities	7 800
Long-term bank loans	-	Share capital	38 632
Issued bonds	-	Statutory reserve	-
Other long-term loans	7 800	Non-restricted equity	-11 443
Long-term liabilities	7 800	Equity	27 189
Net liabilities	9 398	Total equity and liabilities	37 278

For further information, please contact:

Emanuel Björne, CEO Hansa Medical AB

Mobile: +46 707 17 54 77

E-mail: emanuel.bjorne@hansamedical.com

ABOUT HANSA MEDICAL

Hansa Medical is a biopharmaceutical development company focused on inflammation. The company develops innovative biopharmaceuticals and diagnostics in partnership with major companies with market presence as well as under full Hansa Medical management. At present, three primary product candidates are in development; IdeS, anti-alpha-11 and HMD-301. Novel research projects and product candidates are generated through academic collaborations and in-house development. Hansa Medical is publicly traded at NASDAQ OMX First North under ticker symbol HMED. Remium AB is Certified Adviser to Hansa Medical.

Hansa Medical AB
P.O. Box 785
SE-220 07 Lund, SWEDEN
Phone +46 46 16 56 70
Fax +46 46 12 77 75
info@hansamedical.com
www.hansamedical.com

VISITING ADDRESS:
Scheelevägen 22
Lund, SWEDEN